Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

Phase 2TerminatedNCT00137332

Wyeth is now a wholly owned subsidiary of Pfizer90 enrolled

Overview

The purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Arrhythmia

Interventions

GAP-486 (ZP-123)DRUG

0.9% Sodium Chloride, USPDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with or without ICDs (implantable cardioverter defibrillators) * Patients undergoing an electrophysiology study for evaluation of ventricular rhythm * Patients with a history of heart disease Exclusion Criteria: * Patients with uncontrolled blood pressure * Patients with certain cardiac risk factors * Patients with significant kidney or liver problems

Locations (33)

Unnamed facility

Sacramento, California, United States

Outcomes

Primary Outcomes

The measure to determine the effect of the intervention will be whether abnormally fast heart rhythm can be induced after test drug is administered.

Secondary Outcomes

This study takes place within 24 hours, and looks at whether the test article makes a difference in inducing the abnormally fast heart rhythm during a 24 hour observational period.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.